By Denny Jacob
SpringWorks Therapeutics shares rose 36% after Reuters reported Germany's Merck KGaA is in advanced talks to buy the company.
Shares were trading around $54.66. The stock is up 16% over the last year and hit a new 52-week high earlier in the session.
The report said the deal for the cancer and rare diseases biotech company could be finalized in the coming weeks. Merck KGaA told Reuters it would continuously assess options and announce any transactions as and when they materialize, while Stamford, Conn.-based Springworks declined to comment.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
February 10, 2025 11:23 ET (16:23 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.